Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR) and Tandem Diabetes Care (TNDM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals (ACADResearch Report), Nektar Therapeutics (NKTRResearch Report) and Tandem Diabetes Care (TNDMResearch Report).

ACADIA Pharmaceuticals (ACAD)

In a report issued on December 6, Marc Goodman from Leerink Partners maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $31.00. The company’s shares closed last Wednesday at $21.78, close to its 52-week low of $15.68.

According to TipRanks.com, Goodman is a 1-star analyst with an average return of -1.3% and a 41.2% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals.

Currently, the analyst consensus on ACADIA Pharmaceuticals is a Moderate Buy with an average price target of $27.42, which is a 27.0% upside from current levels. In a report issued on December 7, JMP Securities also reiterated a Buy rating on the stock with a $39.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Nektar Therapeutics (NKTR)

In a report issued on December 7, Daina Graybosch from Leerink Partners maintained a Hold rating on Nektar Therapeutics, with a price target of $18.00. The company’s shares closed last Wednesday at $12.73, close to its 52-week low of $10.59.

According to TipRanks.com, Graybosch is ranked 0 out of 5 stars with an average return of -7.6% and a 30.1% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Bolt Biotherapeutics.

Nektar Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $25.67.

Tandem Diabetes Care (TNDM)

Leerink Partners analyst Danielle Antalffy maintained a Hold rating on Tandem Diabetes Care on December 6 and set a price target of $140.00. The company’s shares closed last Wednesday at $140.16, close to its 52-week high of $143.67.

According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 12.8% and a 53.2% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.

Tandem Diabetes Care has an analyst consensus of Moderate Buy, with a price target consensus of $146.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACAD: